yemenjmedYemen Journal of MedicinecoVolume 4 Issue 1MultidisciplinaryEnglishJanuary- April 2025NNY20250522ArticleMetformin – A New Frontier in Skin Cancer PharmacotherapyEnglishY6578Philip O.Ogbeye1EnglishN4EnglishY  Ebisindor V.Awala2EnglishY4EnglishY  Darlington A.Dovieme1EnglishY4EnglishY  OyeintonbaraMiediegha1EnglishY4EnglishYSamuel J.Bunu1EnglishY3EnglishY4EnglishY10.63475/yjm.v4i1.0091Metformin, a widely prescribed biguanide for type 2 diabetes, has emerged as a promising candidate in skin cancer therapy due to its diverse anticancer mechanisms. Beyond its glucose-lowering effects, metformin inhibits key oncogenic pathways, including the PI3K/AKT/mTOR and insulin/IGF-1 signaling pathways, activates AMP-activated protein kinase, and disrupts mitochondrial complex I function. These mechanisms are presumed to contribute to metformin's antiproliferative, pro-apoptotic, and anti-inflammatory effects, potentially reducing tumor growth and metastasis in melanoma and non-melanoma skin cancers.  Predictive molecular docking studies reveal that metformin interacts with critical proteins in melanoma pathophysiology. Against PI3K/mTOR (PDB: 5OQ4), PTPN2 (PDB: 7UAD), and TRIP13 (PDB: 5VQA), metformin exhibited docking scores of -4.4, -4.6, and -5.6 kcal/mol, respectively, interacting via hydrogen bonding with residues such as ASP-836, ASP-964 (5OQ4), ASP-50 (7UAD), and SER-187, SER-138 (5VQA). Compared to standard inhibitors, PQR309 (-9.4 kcal/mol), ABBV-CLS-484 (-7.5 kcal/mol), and ATP (-10.8 kcal/mol), metformin displayed moderate binding affinity, suggesting potential but weaker inhibition of these targets. Preclinical and clinical studies support metformin's potential to reduce skin cancer risk, particularly in diabetic patients. However, challenges regarding bioavailability, optimal dosing, and patient selection persist, necessitating further investigation. Therefore, given its affordability, safety, and multitargeted action, metformin represents an attractive candidate for repurposing in skin cancer pharmacotherapy. Focusing future research on optimizing its therapeutic application, refining drug combinations, and identifying biomarkers would enhance clinical outcomes.EnglishMetformin, Melanoma, Ultraviolet Radiationhttps://yemenjmed.com/admin/abstract?id=145References1619Hofmann E, Schwarz A, Fink J, Kamolz LP, and;amp; Kotzbeck P. Modeling the complexity of human skin in vitro. Biomedicines. 2023; 11(3): 794.Carter E. Identifying types of skin cancer, risk factors, and effective treatments. International Journal of Advanced Engineering Technologies and Innovations. 2024; 10(2): 79-98.Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Medicine. 2021; 9: 20503121211034366.Iragorri N, de Oliveira C, Fitzgerald N, and;amp; Essue B. The out-of-pocket cost burden of cancer careand;mdash;a systematic literature review. Current Oncology. 2021; 28(2): 1216-1248.Lv Z, and;amp; Guo Y. Metformin and Its Benefits for Various Diseases. Frontiers in endocrinology. 2020; 11, 191.Roky AH, Islam MM, Ahasan AMF, Mostaq MS, Mahmud MZ, Amin MN, et al. and;nbsp;Overview of skin cancer types and prevalence rates across continents. Cancer Pathogenesis and Therapy. 2024; 2: E01-E36.Urban K, Mehrmal S, Uppal P, Giesey RL, and;amp; Delost GR. The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990and;ndash;2017. JAAD international. 2021; 2: 98-108.Dode E, Bunu SJ, and;amp; Ikoi AI. Comparative in-vitro bioequivalence analysis of metformin hydrochloride tablet formulations available in Yenagoa Metropolis, Bayelsa State, Nigeria. J. Chem. Res. Adv. 2023; 04(01): 21-26.Patel JJ, and;amp; Mundi MS. Metformin for Type 2 Diabetes. JAMA. 2019; 322(13): 1312.Bailey CJ, and;amp; Day C. Metformin: its botanical background. Practical diabetes international. 2004; 21(3): 115-117.Bailey CJ, and;amp; Day C. Traditional plant medicines as treatments for diabetes. Diabetes care. 1989; 12(8): 553-564.Bailey CJ, and;amp; Turner RC. Metformin. New England Journal of Medicine. 1996; 334(9): 574-579.Bailey CJ. Metformin: historical overview. Diabetologia. 2017; 60(9):1566-1576.World BioChemicals Industries Ltd. (n.d.). Metformin HCl. Available at: https://www.wbcil.com/organic-molecules/metformin-hcl/. Accessed April 05, 2025.Werner EA, Bell J. CCXIV, The preparation of methylguanidine, and and;beta;and;beta;-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides, respectively. Journal of the Chemical Society, Transactions. 1922; 121: 1790-1794.Pasik C. Diabetes and the biguanides: the mystery of each. Glucophage: serving diabetology. 1997; 40: 79.Rathke B. Ueber biguanid. Berichte der deutschen chemischen Gesellschaft. 1879 12(1): 776-784.Claro AE, Palanza C, Mazza M, Schuenemann GEU, Rigoni M, Pontecorvi A, et al. Historical use of medicinal plants and future potential from phytotherapy to phytochemicals. Annali di Botanica. 2024; 14(1).Chen KK, Anderson RC. The toxicity and general pharmacology of N1-p-chlorophenyl-N5-isopropyl biguanide. The Journal of Pharmacology and Experimental Therapeutics. 1947; 91(2): 157-160.Curd FHS, Davey DG, Rose FL. Studies on synthetic antimalarial drugs; some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. Annals of Tropical Medicine and Parasitology. 1945; 39: 208-216.Sterne J. Treatment of diabetes mellitus with N, N-dimethylguanylguanidine (LA. 6023, Glucophage). Therapie. 1959; 14: 625-630.McKendry JBR, Kuwayti K, and;amp; Rado PP. Clinical experience with DBI (phenformin) in the management of diabetes. Canadian Medical Association Journal. 1959; 80(10): 773.Ungar G, Freedman L, and;amp; Shapiro SL. Pharmacological studies of a new oral hypoglycemic drug. Proceedings of the Society for Experimental Biology and Medicine. 1959; 95(1): 190-192.Lalau J. D. Lactic acidosis induced by metformin: incidence, management and prevention. Drug safety. 2010; 33(9): 727-740.Luft D, Schmand;uuml;lling RM, and;amp; Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia. 1978; 14: 75-87.Bailey CJ, and;amp; Nattrass M. 11 Treatmentand;mdash;metformin. Bailliereand;#39;s clinical endocrinology and metabolism. 1988; 2(2): 455-476.Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discovery. 2012; 2(9): 778-790.Zhao H, Swanson KD, Zheng B.and;nbsp; Therapeutic Repurposing of Biguanides in Cancer. Trends in Cancer. 2021; 7(8): 714-730.Bailey CJ, Campbell IW, Chan JCN, Davidson JA, Howlett HCS, Ritz P. (Eds.). Metformin and;ndash; The gold standard: a scientific handbook. Wiley, 2007. Retrieved February 28, 2025, from https://research.aston.ac.uk/en/publications/metformin-the-gold-standard-a-scientific-handbook.DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England Journal of Medicine. 1995; 333(9): 541-549.Kasznicki J, Sliwinska A, and;amp; Drzewoski J. Metformin in cancer prevention and therapy. Annals of translational medicine. 2014; 2(6): 57.Zhang Y, Zhou F, Guan J, Zhou L, and;amp; Chen B. Action mechanism of metformin and its application in hematological malignancy treatments: a review. Biomolecules. 2023; 13(2): 250.Vial G, Detaille D, and;amp; Guigas B. Role of mitochondria in the mechanism (s) of action of metformin. Frontiers in endocrinology. 2019; 10: 294.Khilnani G. Metformin: A Reflection on My Journey as an Antidiabetic Drug. GAIMS Journal of Medical Sciences. 2023; 3(2):and;nbsp; 34-40.Gordon R. (2013). Skin cancer: an overview of epidemiology and risk factors. In Seminars in Oncology Nursing. WB Saunders. 2013; 29(3): 160-169.Khan NH, Mir M, Qian L, Baloch M, Khan MFA, Ngowi EE, et al.and;nbsp; Skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures. Journal of Advanced Research. 2022; 36: 223-247.and;Scaron;erman N, Vranić S, Glibo M, and;Scaron;erman L, and;amp; Mokos ZB. Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review. Bosnian journal of basic medical sciences. 2022; 22(5): 673.Wu S, Cho E, Li, WQ, Weinstock MA, Han J, and;amp; Qureshi AA. History of severe sunburn and risk of skin cancer among women and men in 2 prospective cohort studies. American journal of epidemiology. 2016; 183(9): 824-833.Ciążyńska M, Kamińska-Winciorek G, Lange D, Lewandowski B, Reich A, Sławińska M, et al. The incidence and clinical analysis of non-melanoma skin cancer. Scientific reports. 2021; 11(1): 4337.Griffin LL, Ali FR, and;amp; Lear JT. Non-melanoma skin cancer. Clinical medicine. 2016; 16(1): 62-65.Kasumagic-Halilovic E, Hasic M, and;amp; Ovcina-Kurtovic N. A clinical study of basal cell carcinoma. Medical archives. 2019; 73(6): 394.Kallini JR, Hamed N, and;amp; Khachemoune A. Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. International journal of dermatology. 2015; 54(2): 130-140.Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: From pathogenesis to therapy (Review). International Journal of Oncology. 2018 52: 1071-1080.Liu-Smith F, Jia J, and;amp; Zheng Y. UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer. Ultraviolet light in human health, diseases, and the environment. 2017; 27-40.Bunu SJ, Cai H, Wu L, Zhang H, Zhou Z, Xu Z, et al. TRIP13 - a potential drug target in cancer pharmacotherapy.and;nbsp;Bioorganic chemistry. 2024;and;nbsp;151: 107650.Wang Y. Matrix Remodeling Associated 7 (MXRA7): A Long-lost Member of the Non-kin MXRA Family. Chinese Journal of Biochemistry and Molecular Biology. 2020; 36(7): 725-733Jaune E, and;amp; Rocchi S. Metformin: Focus on melanoma. Frontiers in endocrinology. 2018; 9: 472.Tseng HW, Shiue YL, Tsai KW, Huang WC, Tang PL, and;amp; Lam HC. Risk of skin cancer in patients with diabetes mellitus: a nationwide retrospective cohort study in Taiwan. Medicine. 2016; 95(26): e4070.Koury J, Lucero M, Cato C, Chang L, Geiger J, Henry, D, et al. Immunotherapies: Exploiting the Immune System for Cancer Treatment. Journal of Immunology Research. 2018; 2018: 9585614.Kumar AR, Devan AR, Nair B, Vinod BS, and;amp; Nath LR. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Molecular biology reports. 2021; 48(12): 8075and;ndash;8095.Czarnecka AM, Bartnik E, Fiedorowicz M, and;amp; Rutkowski P. Targeted Therapy in Melanoma and Mechanisms of Resistance. International journal of molecular sciences. 2020; 21(13): 4576.Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, et al. BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers. 2020; 12(7): 1823.Serrone L, Zeuli M, Sega FM, and;amp; Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. Journal of experimental and;amp; clinical cancer research: CR. 2000; 19(1): 21and;ndash;34.Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006; 106(2): 375and;ndash;382.Kaur R, Bhardwaj A, and;amp; Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Molecular biology reports. 2023; 50(11): 9663and;ndash;9676.Mehta A, Motavaf M, Nebo I, Luyten S, Osei-Opare KD, and;amp; Gru AA. Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy. Journal of Clinical Medicine. 2025; 14(4): 1200.Miller RA, and;amp; Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. The Journal of Clinical Investigation. 2010; 120(7): 2267-2270.Ke R, Xu Q, Li C, Luo L, and;amp; Huang D. Mechanisms of AMPK in the maintenance of ATP balance during energy metabolism. Cell Biology International. 2018; 42(4): 384-392.Gonga L, Goswamic S, Giacominic KM, Altmana RB, and;amp; Kleina TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012; 22(11): 820-827.Lewis A, Williams K, and;amp; Oroszi T. Metforminand;mdash;Pharmacokinetic and Pharmacodynamics Journey Through the Body. Pharmacology and;amp; Pharmacy. 2024;15(12): 466-477.San KIH. The use of metformin in patients with renal impairment; Doctoral dissertation, University of Otago, 2020.Yasin MT. A review on metformin for the treatment of type II Diabetes Mellitus; Doctoral dissertation, Brac University, 2024.Saleh J, Yusuph H, and;amp; Aji B. Combination of Metformin and Thiazolidinediones in Type 2 Diabetes Mellitus- A Review. Nigerian Hospital Practice. 2009; 3: 3-4.Gong L, Goswami S, Giacomini KM, Altman RB, and;amp; Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics. 2012; 22(11): 820and;ndash;827.Bristol-Myers S. GLUCOPHAGE- metformin hydrochloride tablet, film-coated GLUCOPHAGE XR- metformin hydrochloride tablet, extended-release, patient information leaflet, 2019, https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=453104.Heller JB. Metformin overdose in dogs and cats. Veterinary Medicine-Bonner Springs then Edwardsville. 2007; 102(4): 231.Hougen I, Whitlock RH, Komenda P, Rigatto C, Clemens KK, and;amp; Tangri N. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study. BMJ Open Diabetes Research and;amp; Care. 2021; 9(2): e002352.Sheleme T. Clinical Pharmacokinetics of Metformin. In www.intechopen.com. IntechOpen, 2021. https://www.intechopen.com/chapters/77996.Lei Y, Yi Y, Liu Y, Liu X, Keller ET, Qian C, et al. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer. 2017; 36(1): 17.Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis.and;nbsp;eLife. 2014:and;nbsp;3: e02242.Hur KY, and;amp; Lee MS. New mechanisms of metformin action: Focusing on mitochondria and the gut. Journal of diabetes investigation. 2015; 6(6): 600-609.Meng S, Cao J, He Q, Xiong L, Chang E, Radovick S, et al. Metformin activates AMP-activated protein kinase by promoting formation of the and;alpha;and;beta;and;gamma; heterotrimeric complex.and;nbsp;The Journal of Biological Chemistry. 2015;and;nbsp;290(6): 3793and;ndash;3802.Kim I, and;amp; He YY. Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy.and;nbsp;Frontiers in Oncology. 2013;and;nbsp;3: 175.Gallagher EJ, and;amp; LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Annals of the New York Academy of Sciences. 2011; 1243(1): 54-68.Ding XZ, Fehsenfeld DM, Murphy LO, Permert J, and;amp; Adrian TE. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase, and enhancing GLUT-1 expression. Pancreas. 2000; 21(3): 310-320.Draznin B. Mechanism of the mitogenic influence of hyperinsulinemia. Diabetology and;amp; metabolic syndrome. 2011; 3: 1-3.Morales DR, and;amp; Morris AD. Metformin in cancer treatment and prevention. Annual review of medicine. 2015; 66(1): 17-29.Sachdev D, and;amp; Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Molecular cancer therapeutics. 2007; 6(1): 1-12.Algire C, Amrein L, Bazile M, David S, Zakikhani M, and;amp; Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 2011 30(10): 1174-1182.Gong J, Kelekar G, Shen J, Shen J, Kaur S, and;amp; Mita M. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. Targeted oncology. 2016; 11: 447-467.Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, et al. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. Journal of Surgical Research. 2010; 160(1): 90-101.Kourelis TV, and;amp; Siegel RD. Metformin and cancer: new applications for an old drug. Medical oncology. 2012; 29: 1314-1327.Lewis D, Travers J, Somani AKand;nbsp;and;amp; Spandau DF. The IGF-1/IGF-1R signaling axis in the skin: a new role for the dermis in aging-associated skin cancer.and;nbsp;Oncogene. 2010;and;nbsp;29: 1475and;ndash;1485.Salminen A, Kaarniranta K, and;amp; Kauppinen A. Photoaging: UV radiation-induced inflammation and immunosuppression accelerate the aging process in the skin. Inflammation Research. 2022; 71(7): 817-831.Chen Q, Zhang H, Yang Y, Zhang S, Wang J, Zhang D, et al. Metformin Attenuates UVA-Induced Skin Photoaging by Suppressing Mitophagy and the PI3K/AKT/mTOR Pathway.and;nbsp;International Journal of Molecular Sciences. 2022;and;nbsp;23(13): 6960.Beaufils F, Cmiljanovic N, Cmiljanovic V, Bohnacker T, Melone A, Marone R, et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.and;nbsp;Journal of Medicinal Chemistry. 2017;and;nbsp;60(17): 7524and;ndash;7538.Baumgartner CK, Ebrahimi-Nik H, Iracheta-Vellve A, Hamel KM, Olander KE, Davis TGR, et al. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.and;nbsp;Nature. 2023;and;nbsp;622(7984): 850and;ndash;862.Ye Q, Kim DH, Dereli I, Rosenberg SC, Hagemann G, Herzog F, et al. The AAA+ ATPase TRIP13 remodels HORMA domains through N-terminal engagement and unfolding.and;nbsp;The EMBO Journal. 2017;and;nbsp;36(16): 2419and;ndash;2434.Ma J, Cai X, Kang L, Chen S, and;amp; Liu H. Identification of novel biomarkers and candidate small-molecule drugs in cutaneous melanoma by comprehensive gene microarray analysis.and;nbsp;Journal of Cancer. 2021;and;nbsp;12(5): 1307and;ndash;1317.Lu W, Mengxuan Z, Ming R, Zixu G, Yong Z, Simin Z, et al.and;nbsp; TRIP13/FLNA Complex Promotes Tumor Progression and Is Associated with Unfavorable Outcomes in Melanoma.and;nbsp;Journal of Oncology.and;nbsp;2022: 1419179.Schrand;ouml;dinger. Maestro Programme, Schrand;ouml;dinger.and;nbsp; LLC, New York, NY. S, 2020.Tseng CH. Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes. Journal of the American Academy of Dermatology. 2018; 78(4): 694-700.Adalsteinsson JA, Muzumdar S, Waldman R, Wu R, Ratner D, Feng H, et al. Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland. Journal of the American Academy of Dermatology. 2021; 85(1): 56-61.ClinicalTrials.gov. (n.d.). A Phase I/II trial of vemurafenib and metformin to melanoma patients - Full-text view. U.S. National Library of Medicine. Retrieved from https://clinicaltrials.gov/ct2/show/NCT01638676ClinicalTrials.gov. (n.d.). Efficacy and safety of metformin in patients with type 1 diabetes (NCT02143050). U.S. National Library of Medicine. Retrieved 27th February 2025, from https://clinicaltrials.gov/study/NCT02143050.ClinicalTrials.gov. (n.d.). Study of Metformin in Patients with Kidney Disease (NCT03311308). U.S. National Library of Medicine. Retrieved 27th February 2025, from https://clinicaltrials.gov/study/NCT03311308.Saraei P, Asadi I, Kakar MA, and;amp; Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer management and research. 2019; 11: 3295and;ndash;3313.Suwei D, Yanbin X, Jianqiang W, Xiang M, Zhuohui P, Jianping K, et al. Metformin inhibits melanoma cell metastasis by suppressing the miR-5100/SPINK5/STAT3 axis. Cellular and;amp; molecular biology letters. 2022 27(1): 48.Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell death and;amp; disease. 2011; 2(9): e199.Souza-Neto FP, Marinello PC, Melo GP, Ramalho LZN, Cela EM, Campo VE, et al. Metformin inhibits the inflammatory and oxidative stress response induced by skin UVB irradiation and provides 4-hydroxy-2-nonenal and nitrotyrosine formation and p53 protein activation. Journal of Dermatological Science. 2020; 100(2): 152and;ndash;155.Vander HMG. Targeting cancer metabolism: a therapeutic window opens. Nature reviews Drug discovery. 2011; 10(9): 671-684.Ward PS, and;amp; Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer cell. 2012; 21(3): 297-308.Carstensen B, Witte DR, and;amp; Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012; 55: 948-958.Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, and;amp; Walker. Reduction in the incidence 3 of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(4): 393and;ndash;403.Pollak M. Metformin and Other Biguanides in Oncology: Advancing the Research Agenda. Cancer Prevention Research (Philadelphia, Pa.). 2010; 3(9): 1060-1065.Kumbhar P, Kole K, Yadav T, Bhavar A, Waghmare P, Bhokare R, et al. Drug repurposing: An emerging strategy in alleviating skin cancer. European Journal of Pharmacology. 2022; 926: 175031.Feng H, Shang S, Chen K, Sun X, and;amp; Yue X. Impact of metformin on melanoma: a meta-analysis and systematic review. Frontiers in Oncology. 2024; 14: 1399693.Haq Z, Mirza FN, Abdi P, Diaz MJ, and;amp; Libby TJ. Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study. Journal of Drugs in Dermatology. 2024; 23(12): 1089and;ndash;1095.Weir SJ, DeGennaro LJ, and;amp; Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnerships. Cancer Research. 2012; 72(5): 1055-1058.Xia Y, Sun M, Huang H, and;amp; Jin WL. Drug repurposing for cancer therapy. Signal transduction and targeted therapy. 2024; 9(1): 92.